<DOC>
	<DOCNO>NCT00499967</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability activity GS-9191 ointment treatment genital wart . GS-9191 ointment intend topical application directly genital wart skin .</brief_summary>
	<brief_title>Safety Effectiveness Study Experimental Topical Ointment ( GS-9191 ) Treatment Genital Warts</brief_title>
	<detailed_description />
	<mesh_term>Warts</mesh_term>
	<mesh_term>Condylomata Acuminata</mesh_term>
	<criteria>Have 2 genital wart prespecified sizes external surface body . If HIV positive , HIV RNA &lt; 400 copies/mL , CD4 count â‰¥ 400 cells/mm3 , take triple combination antiviral medication regimen Prior genital wart treatment within 8 week Pregnancy breastfeed Presence broken nonintact skin near wart site skin disease wart site ( e.g. , herpes genitalis ) Treatment systemic steroid , systemic immunomodulators , immunosuppressant , chemotherapeutic agent within 3 month Current prior diagnosis Bowenoid papulosis , cancer , precancerous tissue genital area</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>genital wart</keyword>
	<keyword>venereal wart</keyword>
	<keyword>human papilloma virus</keyword>
</DOC>